Published in Acta Oncol on January 01, 1989
Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer (2005) 0.83
N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines. Heliyon (2016) 0.77
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry (1983) 2.32
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry (1983) 1.56
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol (2002) 1.49
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet (1996) 1.47
Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.44
Long-term storage of samples for flow cytometric DNA analysis. Cytometry (1983) 1.36
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs (1998) 1.30
Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.28
In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta (1999) 1.24
Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol (1977) 1.21
Cellular resistance to anthracyclines. Gen Pharmacol (1996) 1.19
Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res (1982) 1.18
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol (1998) 1.15
Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet (1987) 1.15
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta (1997) 1.15
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol (2001) 1.11
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol (2002) 1.09
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta (1997) 1.08
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res (1980) 1.05
Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer (1987) 1.03
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A (1973) 1.02
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer (1983) 1.02
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta (1992) 1.02
Membrane transport of anthracyclines. Pharmacol Ther (1982) 1.00
Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst (1987) 1.00
Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med (1988) 0.99
Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur J Haematol (1989) 0.98
Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest (1992) 0.98
Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol (1978) 0.98
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol (2000) 0.95
Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer (1981) 0.94
Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem (1996) 0.93
Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res (1983) 0.93
Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer (1988) 0.91
Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res (1979) 0.91
Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev (1984) 0.89
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). Cancer (1980) 0.89
Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res (1980) 0.89
Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol (1987) 0.88
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol (2002) 0.87
Synchronization of the human promyelocytic cell line HL 60 by thymidine. Cell Tissue Kinet (1986) 0.87
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim Biophys Acta (1997) 0.86
Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol (1985) 0.86
PHASE I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep (1976) 0.84
Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol (1992) 0.83
Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat Rep (1982) 0.83
Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep (1972) 0.83
Thyroid function in malignant lymphoma. Acta Med Scand (1977) 0.83
Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma. J Am Acad Dermatol (1986) 0.83
Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol (1993) 0.82
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol (1993) 0.82
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem (1993) 0.82
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer (1989) 0.82
Fatal hepatitis following irradiation and vincristine. Acta Med Scand (1982) 0.82
A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leuk Lymphoma (1992) 0.81
The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Recent Results Cancer Res (1980) 0.81
Clinical trial with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep (1972) 0.81
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells. Biochem Pharmacol (1989) 0.81
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells. Br J Cancer (1990) 0.81
Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep (1982) 0.81
Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia. Br J Haematol (1980) 0.80
Immunohistochemical identification of lymphocyte subsets and accessory cells in human hyperplastic lymph nodes. The functional significance of the compartmentalization of lymphoid tissue. Scand J Haematol (1984) 0.80
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep (1982) 0.80
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators. Br J Cancer (1989) 0.80
Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol (1986) 0.80
Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand (1969) 0.80
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother Pharmacol (1990) 0.79
Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol (1988) 0.79
Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep (1972) 0.79
Prognostic significance of tumour burden in Hodgkin's disease PS I and II. Scand J Haematol (1986) 0.79
Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res (1973) 0.79
The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells. Biochem Pharmacol (1988) 0.79
Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochem Pharmacol (2000) 0.79
Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Cancer Chemother Rep (1975) 0.79
pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells. Cell Physiol Biochem (1998) 0.79
Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann Oncol (1992) 0.79
Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up. Eur J Cancer (1992) 0.79
In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor. Cancer Chemother Pharmacol (1979) 0.78
Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand (1983) 0.78
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer (1993) 0.78
Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys (2001) 0.78
Changes over the course of time in histological subclassification of Hodgkin's disease in Denmark. Dan Med Bull (1991) 0.78
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil. Biochem Pharmacol (1995) 0.78
Clinical experience with bacteraemia in patients with leukaemia and allied neoplastic diseases. Chemotherapy (1978) 0.78
Interaction among two subpopulations of Ehrlich ascites tumor in vivo: evidence of a contact mediated immune response. Acta Pathol Microbiol Immunol Scand A (1987) 0.78
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer (1993) 0.78
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep (1984) 0.78
Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol Suppl (1987) 0.77
Phase I trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep (1979) 0.77
Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity. Cancer Treat Rep (1983) 0.77